According to Zacks, “908 Devices Inc. is a purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis. It conducts research, designs and manufactures products of mass spectrometry, microfluidic separations, software automation and machine learning. 908 Devices Inc. is headquartered in Boston. “
MASS stock opened at $17.65 on Wednesday. The company has a quick ratio of 11.42, a current ratio of 12.06 and a debt-to-equity ratio of 0.12. 908 Devices has a 1 year low of $16.98 and a 1 year high of $79.60. The company has a fifty day simple moving average of $25.39 and a 200 day simple moving average of $31.02.
In other 908 Devices news, VP John Kenneweg sold 10,000 shares of the business’s stock in a transaction on Monday, October 18th. The shares were sold at an average price of $32.22, for a total transaction of $322,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Joseph H. Iv Griffith sold 2,800 shares of the business’s stock in a transaction on Friday, November 5th. The stock was sold at an average price of $39.08, for a total transaction of $109,424.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 67,100 shares of company stock valued at $2,107,519. Company insiders own 51.10% of the company’s stock.
Several large investors have recently bought and sold shares of MASS. Swiss National Bank bought a new position in shares of 908 Devices during the 2nd quarter worth about $581,000. Rafferty Asset Management LLC bought a new position in shares of 908 Devices during the 2nd quarter worth about $3,454,000. Nicholas Investment Partners LP increased its holdings in shares of 908 Devices by 15.6% during the 2nd quarter. Nicholas Investment Partners LP now owns 357,858 shares of the company’s stock worth $13,867,000 after purchasing an additional 48,224 shares during the period. BlackRock Inc. increased its holdings in shares of 908 Devices by 198.3% during the 2nd quarter. BlackRock Inc. now owns 2,457,309 shares of the company’s stock worth $95,220,000 after purchasing an additional 1,633,500 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in shares of 908 Devices by 14.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,566 shares of the company’s stock worth $1,300,000 after purchasing an additional 4,291 shares during the period. Institutional investors own 57.34% of the company’s stock.
908 Devices Company Profile
908 Devices Inc develops and sells measurement devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers handheld and desktop mass spectrometry (Mass Spec) devices for the point-of-need applications in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.
Further Reading: Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.